2. Signaling Pathways
  3. Neuronal Signaling
  4. α-synuclein

α-synuclein

α-Syn

α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-synuclein regulates synaptic vesicle trafficking and subsequent neurotransmitter release. Genetics and neuropathology studies link α-synuclein to Parkinson's disease (PD) and other neurodegenerative disorders. Accumulation of misfolded oligomers and larger aggregates of α-synuclein defines multiple neurodegenerative diseases called synucleinopathies, but the mechanisms by which α-synuclein acts in neurodegeneration are unknown.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-16009
    Buntanetap
    		Inhibitor 99.71%
    Buntanetap ((+)-Phenserine) is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease.
    Buntanetap
  • HY-132845
    Utreloxastat
    		99.69%
    Utreloxastat (PTC857) is an orally active 15-lipoxygenase inhibitor that can cross the blood-brain barrier. Utreloxastat is a weak inhibitor of CYP1A2 and 2B6 with an IC50 > 5.3 μM. Utreloxastat reduces oxidative stress and inhibits the consumption of reduced glutathione and ferroptosis. Utreloxastat can be used in the study of neurodegenerative diseases characterized by high levels of oxidative stress and mitochondrial pathology, such as amyotrophic lateral sclerosisc.
    Utreloxastat
  • HY-124876
    SynuClean-D
    		99.89%
    SynuClean-D (SC-D) is an inhibitor of α-synuclein aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease.
    SynuClean-D
  • HY-Y0790
    Cuminaldehyde
    		Inhibitor 99.03%
    Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC50= 0.00085 mg/mL), α-glucosidase (IC50=0.5 mg/mL) and lipoxygenase (IC50=1370 μM). Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases.
    Cuminaldehyde
  • HY-107811
    Harmol
    		Inhibitor 99.77%
    Harmol is a TFEB activator, an orally active monoamine oxidase inhibitor that has anti-tumor, anti-depressant, and anti-aging effects. Harmol can induce cell mitosis, autophagy and apoptosis. Harmol promotes the degradation of α-synuclein through the regulation of the autophagy-lysosomal pathway, improving motor deficits in mouse models of Parkinson's disease.
    Harmol
  • HY-121252
    Dopal
    Dopal is an aldehyde that can be generated in Parkinson's disease by enzymatic degradation of dopamine. Dopal can generate reactive oxygen species, and triggers aggregation of α-synuclein. DOPAL elicits α-synuclein accumulation and hampers α-synuclein clearance in primary neurons.
    Dopal
  • HY-159945
    tau Protein/α-synuclein-IN-2
    		Inhibitor
    Tau Protein/α-synuclein-IN-2 (Compound 14T) is a blood-brain barrier penetrating tau and α-syn inhibitor. Through its thiourea linker structure, Tau Protein/α-synuclein-IN-2 dose-dependently reduces α-syn oligomerization. In biosensor cells, Tau Protein/α-synuclein-IN-2 prevents the seeding effect of tau aggregation. In the M17D neuroblastoma model, Tau Protein/α-synuclein-IN-2 exhibits anti-inclusion effects. Additionally, Tau Protein/α-synuclein-IN-2 reduces Aβ plaque formation. Tau Protein/α-synuclein-IN-2 holds promise for Alzheimer's disease and Parkinson's disease research.
    tau Protein/α-synuclein-IN-2
  • HY-159941
    tau-0N4R-IN-1
    		Inhibitor
    tau-0N4R-IN-1 (Compound 6T) is an BBB-penetrable inhibitor of tau 0N4R oligomerization. tau-0N4R-IN-1 effectively inhibits the fibrosis of tau 0N4R, 2N3R, and 2N4R, exhibits an anti-seeding effect on tau in vitro, reduces the oligomerization of α-syn dose-dependently, and prevents formation of α-syn inclusions. tau-0N4R-IN-1 is stable in mouse microsomes and reduces Aβ plaques in brain tissues from AD patients. tau-0N4R-IN-1 has good pharmacokinetic properties in mice.
    tau-0N4R-IN-1
  • HY-N0743
    Senkyunolide A
    		Inhibitor 99.92%
    Senkyunolide A is a phthalein compound. Senkyunolide A inhibits the proliferation of tumor cells and has anticancer activity. Senkyunolide A inhibits the progression of osteoarthritis through the NLRP3 signaling pathway. Senkyunolide A protects nerve cells from Corticosterone (HY-B1618) -induced apoptosis by regulating protein phosphatase 2A and α-synuclein signaling pathways. Senkyunolide A inhibits the expression of CD137, a diagnostic biomarker for atherosclerosis.
    Senkyunolide A
  • HY-155021
    PROTAC α-synuclein degrader 5
    		Degrader 99.71%
    PROTAC α-synuclein degrader 5 is a highly selective small-molecule degraders (PROTAC) of α-synuclein aggregates, with an DC50 of 7.51 μM and the highest degradation rate Dmax of 89%. PROTAC α-synuclein degrader 5 contains probe molecule sery308 and E3 ligase ligands. PROTAC α-synuclein degrader 5 can be used for neurological disease research.
    PROTAC α-synuclein degrader 5
  • HY-157839
    PROTAC α-synuclein degrader 6
    		Degrader 99.05%
    PROTAC α-synuclein degrader 6 (compound T3) is a PROTAC degrader of α-synuclein and tau, with EC50 of 1.57 μM and 4.09 μM, respectively. PROTAC α-synuclein degrader 6 plays an important role in neurodegenerative diseases (NDs) research (Blue:ubiquitin E3 ligase cereblon ligand (HY-14658), Black: linker (HY-128803); Pink: Ligand for target protein (HY-151035)).
    PROTAC α-synuclein degrader 6
  • HY-N0901A
    Corynoxine B
    		Inducer 99.76%
    Corynoxine B is a natural alkaloid and autophagy inducer that can improve Mn induced cellular autophagy dysregulation and enhance clearance of alpha synuclein (alpha syn) in Parkinson's disease mice[1][3].
    Corynoxine B
  • HY-120475A
    PBT434 mesylate
    		Inhibitor 99.92%
    PBT434 methanesulfonate is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 methanesulfonate can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 methanesulfonate inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 methanesulfonate prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 methanesulfonate has the potential for the research of Parkinson’s disease (PD).
    PBT434 mesylate
  • HY-136001
    PROTAC α-synuclein degrader 3
    		Degrader 99.35%
    PROTAC α-synuclein degrader 3 (compound 5) is a potent and selective PROTAC α-synuclein degrader. PROTAC α-synuclein degrader 3 can be used in research of Parkinson's disease.
    PROTAC α-synuclein degrader 3
  • HY-P99405
    Prasinezumab
    		Inhibitor 99.90%
    Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research.
    Prasinezumab
  • HY-P99356
    Cinpanemab
    		Inhibitor
    Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease.
    Cinpanemab
  • HY-145580
    Minzasolmin
    		99.20%
    Minzasolmin is an alpha-synuclein oligomerization inhibitor.
    Minzasolmin
  • HY-160116
    α-Synuclein aggregate binder 1
    		Inhibitor 98.11%
    α-Synuclein aggregate binder 1 (Compound C05-05) is a collective binder and an inhibitor for α-synuclein aggregation. α-Synuclein aggregate binder 1 is utilized in Positron Emission Tomography (PET) imaging and fluorescence microscope, that can diagnose and ameliorate the neurodegenerative disease.
    α-Synuclein aggregate binder 1
  • HY-115038
    ELN484228
    		99.50%
    ELN484228 is a blocker of α-synuclein which is a key protein in Parkinson’s disease.
    ELN484228
  • HY-P4704A
    α-Synuclein (61-95) (human) TFA
    α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD).
    α-Synuclein (61-95) (human) TFA
Cat. No. Product Name / Synonyms Application Reactivity